Assessment of Brain Natriuretic Peptide (BNP) and Lactate Dehydrogenase (LDH) levels in type 2 Diabetic Patients with Cardiovascular Disease

Abstract

The metabolic condition type 2 diabetes mellitus (T2DM) causes organ malfunction and damage due to insulin secretion or resistance abnormalities. The clinical assessment of monitoring short-term blood glucose variability could benefit from the addition of a less interference-prone biomarker for nutritional status and blood cell health. In type 2 diabetic individuals with cardiovascular disease (CVD), this study looks at the significance of serum B-type natriuretic peptide (BNP) and lactate dehydrogenase (LDH) and how it relates to other variables. This study included 100 T2DM patients with cardiovascular disease (57 males and 43 females) with 70 healthy controls (39 males and 31 females ) aged 45 to >74  years with a diabetes duration of 12 to 26 years. the present study shows that in T2DM patients with CVD, there was an increase in Brain Naturiertic Peptide and a high increase in LDH levels. The statistical significance of these differences is very significant (P>0.001). Comparing the patient group to the control group, there is a highly significant increase in BNP and LDH. BNP and LDH were greater in people with type 2 diabetes who also had cardiovascular disease (CVD) and elevated LDH level was associated with elevated BNP. BNP and LDH are useful biomarkers that support diagnosis, and risk assessment, as well as the diagnosis and management of cardiovascular disease in diabetic individuals by facilitating the assessment of heart function and risk factors for cardiovascular disease.